Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc
Bullboard Posts
User Avatar Image
(37)
•••
Comment by wagyusteakon Jul 27, 2020 1:30pm
45 Views
Post# 31325355

RE:RE:RE:Mugs

RE:RE:RE:Mugs
porksniffer wrote:
MUGMODs wrote: I think you are referencing Pharmascience ... and ... we both know that's a private company.  No numbers for you.

But ...

I was thinking about Pharmascience today.
Maybe we could sell for them in LATAM and ROW. 
I wonder if that can happen. 
Hmmmmmmm !!!!


 




No it can't happen you cuck. That was the old ways at Palladin, no longer have this advantage. Not so easy anymore. JRG is suppose to be 'competeing' with them and his stake in PMS is suppose to be in a blind trust as part of the deal to appease Meir and his lawyers. He's not suppose to have any info to the going on inside Pharmascience. This is why the share price is where it is....cause the PARENT is no longer availabe to funnel drugs downwards to sell. Any more bs you care to post here? Like how you keep 'accumulating' lmao

Everything Meir said woyuld happen, has happened. Everything.


 


oh, hi there,... Meir's cuck sucker. Lolllll

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities